IP Library Granted Patent US 10,562,854
Granted Patent B2
US 10,562,854 · App. 15/900,447 · Granted Feb 18, 2020

Prolyl hydroxylase inhibitors

Inventors: Joseph H. Gardner (Cincinnati, OH); Robert Shalwitz (Bexley, OH); Shengde Wu (Mason, OH)
Assignee: AERPIO THERAPEUTICS, INC.
C07D211/96A61K31/44A61K31/444A61K31/4412A61K31/4427A61K31/4439A61K31/4545A61K31/496A61K31/501A61K31/5377A61K31/541A61K31/55A61K45/06C07D211/86C07D213/02C07D213/69C07D401/06C07D401/14C07D417/06C07D491/113Y02A50/401Y02A50/465Y02A50/47Y02A50/471Y02A50/473Y02A50/475Y02A50/478Y02A50/481
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,562,854
App. No.
15/900,447
Granted
Feb 18, 2020
Kind
B2
Abstract

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.

Claims (28)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein

A is piperazinyl;

w is 1;

R 200 is —[C(R 37a )(R 37b )] y C(O)R 27 ;

y is 0;

R 27 is —OR 28 ; and

R 28 is C 1 -C 4 linear alkyl.

2. The compound of claim 1 wherein R 28 is methyl.

3. The compound of claim 1 wherein R 28 is ethyl.

4. The compound of claim 1 wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate.

5. A compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein

n is 0;

A is piperazinyl;

w is 1;

R 200 is —[C(R 37a )(R 37b )] y C(O)R 27 ;

y is 0;

R 27 is —OR 28 ; and

R 28 is C 1 -C 4 linear alkyl.

6. The compound of claim 5 wherein R 14 is methyl.

7. The compound of claim 5 wherein R 14 is ethyl.

8. The compound of claim 5 wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fumarate, glycolate, or citrate.

9. A method for treating an infection, comprising administering to a subject a composition comprising a compound of claim 1 or 5 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

10. The method of claim 9 wherein the wherein the compound is a pharmaceutically acceptable salt of an anion chosen from chloride, bromide, iodide, sulfate, bisulfate, carbonate, bicarbonate, phosphate, hydrogensulfonate, p-toluenesulfonate, methanesulfonate, formate, acetate, propionate, butyrate, pyruvate, lactate, oxalate, malonate, maleate, succinate, tartrate, fomarate, glycolate, or citrate.

11. The method of claim 9 wherein the infection is caused by a pathogen chosen from bacteria, viruses, yeasts, fungi, or parasites.

12. The method if claim 9 wherein the infection is caused by bacteria.

13. The method of claim 12 wherein the bacteria is Staphylococcus aureus, methicillin resistant Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa , or Acinetobacter baumannii .

Assignments (6)
CHANGE OF NAME Recorded Jul 31, 2019
From: AERPIO THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS LLC
Reel/Frame 049919/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: WU, SHENGDE
To: THE PROCTOR & GAMBLE COMPANY
Reel/Frame 047110/0896 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: THE PROCTOR & GAMBLE COMPANY
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 047111/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: AKEBIA THERAPEUTICS, INC.
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 047111/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: AKEBIA THERAPEUTICS, INC
Reel/Frame 047642/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2018
From: GARDNER, JOSEPH H.; SHALWITZ, ROBERT
To: AERPIO THERAPEUTICS, INC.
Reel/Frame 045604/0878 →